Health & Biotech
Incannex Healthcare Limited (IHL.ASX) is a clinical stage pharmaceutical development company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of Generalised Anxiety Disorder (GAD), Obstructive Sleep Apnoea (OSA), Traumatic Brain Injury (TBI)/Concussion, rheumatoid arthritis, inflammatory bowel disease and inflammatory lung conditions (ARDS, COPD, Asthma, Bronchitis).
FDA registration and marketing approval, subject to ongoing clinical success, is being pursued for each product and therapy under development.
Each indication represents major global markets and currently have either no, or limited, existing registered pharmacotherapy (drug) treatments available to the public, raising the possibility of patients receiving Government subsidies for products that demonstrate suitable safety and efficacy profiles in clinical trials.
Incannex has a strong patent filing strategy as it develops its products and therapies in conjunction with its medical and scientific advisory board and its collaborative partners, including Monash University and The Alfred Hospital.
KEY PEOPLE
RELATED STOCKHEAD STORIES
News
ASX Earnings Wrap: Netlinkz revenue grows; Prescient and Incannex march ahead on clinical trials
Health & Biotech
Incannex at forefront of psychedelic research and development with key trial data review kicking off
News
Market Highlights: Goldman sends shudders as profit falls 68pc, and 5 ASX small caps to watch on Wednesday
Health & Biotech
ScoPo’s Powerplays: ASX healthcare sector Christmas rally runs out of puff
Health & Biotech
Eurofins to manufacture Incannex’s topical cannabinoid formulation to treat common skin conditions
Health & Biotech
Incannex appoints Eurofins to manufacture novel addiction treatments CannQuit-N and CannQuit-O
Health & Biotech
Weed Week: Oregon pardons cannabis convictions and bulk people light up on Turkey Day
Health & Biotech
Incannex initiates big clinical trial and details FDA plans for pivotal clinical trials for sleep apnoea drug
News
ASX Quarterlies: Smiles all around as cybersec blossoms, biotechs well-funded to focus on trials
Health & Biotech
Weed Week: Germany’s plans to legalise cannabis rekindle North American investment spark in Europe
Explainers
ASX Cannabis Stocks Guide 2022/23: Here’s everything you need to know
Health & Biotech
Incannex jumps another hurdle to advance to Phase 2 clinical trials of its anti-inflammatory drug
Health & Biotech
ASX Biotech Stocks: This brain training app could catch dementia early and Brainchip nabs more patents
Health & Biotech
Weed Week: US looks to decriminalise cannabis and Victoria Greens say legal weed could mean $1.21bn in revenue
Health & Biotech
Check Up: These 3 biotechs join the elite ASX 300 this week – and it could be a game-changer
Health & Biotech
IHL share price climbs before debuting on S&P/ASX 300 index
News